Bioventus Inc. (BVS) shares soared 6.71% in pre-market trading on Tuesday following the release of its strong third-quarter financial results. The company reported Q3 revenue of $138.7 million, surpassing analyst expectations of $138.2 million, while adjusted earnings per share came in at $0.15, beating the consensus estimate of $0.12.

The medical device company demonstrated robust organic revenue growth of 8.2% year-over-year, driven by above-market growth across all three areas of its portfolio. Bioventus President and CEO Rob Claypoole highlighted the exceptional quarter, noting "momentum continued to build across our portfolio as our team delivered above-market organic revenue growth, increased profitability, and significant cash flow acceleration."

Adding to investor optimism, Bioventus reaffirmed its full-year 2025 financial guidance. The company expects net sales between $560 million and $570 million, representing organic growth of approximately 6.1% to 8.0%. Adjusted EBITDA is projected to be in the range of $112 million to $116 million, with non-GAAP EPS forecasted between $0.64 and $0.68.